Details for Patent: 9,439,921
Which drugs does patent 9,439,921 protect, and when does it expire?
Patent 9,439,921 protects KENGREAL and is included in one NDA.
This patent has twenty-eight patent family members in twenty-two countries.
Summary for Patent: 9,439,921
| Title: | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | The present invention relates to high purity cangrelor, pharmaceutical formulations comprising high purity cangrelor as an active ingredient, methods for preparing such compounds and formulations, and methods for using the pharmaceutical formulations in the inhibition of platelet activation and aggregation. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Panna Dutta, Adel Rafai Far, Min Ding, Rajeshwar Motheram | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Chiesi Farmaceutici SpA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US15/049,727 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,439,921 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Composition; Formulation; Compound; | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | US Patent 9,439,921: Cangrelor Formulation Claims, Patent Scope, Expiration, and Generic RiskUS Patent 9,439,921 protects a stability-controlled formulation of high-purity cangrelor, including formulations containing mannitol and/or sorbitol, low moisture, controlled pH, specified impurity limits, and storage in a sealed vessel under dry inert gas. The patent is formulation-specific rather than a broad patent on cangrelor, its chemical structure, or all uses of the drug. The principal commercial product is Kengreal, an intravenous cangrelor product approved by the FDA in 2015 for reducing the risk of periprocedural myocardial infarction, repeat coronary revascularization, and stent thrombosis in patients undergoing percutaneous coronary intervention who have not received a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.[1] What patent is US 9,439,921?US 9,439,921 is directed to stable pharmaceutical formulations of cangrelor. The patent claims were issued in 2016 and cover both the formulation itself and a sealed-container configuration designed to control moisture and degradation during storage.[2]
The claims use both “comprising” and “consisting of” formulations. That distinction materially affects infringement analysis. What does US Patent 9,439,921 claim?The 26 claims divide into two substantially parallel groups. Claims 1-13 cover a formulation and a sealed vessel containing that formulation. Claims 14-26 repeat the same architecture with a narrower formulation defined as consisting of cangrelor, or a cangrelor salt, and mannitol and/or sorbitol. Claim group 1: formulation and containerIndependent claim 1 requires all of the following:
Claim 14 is narrower in formulation composition. It requires the formulation to consist of cangrelor or a cangrelor salt and mannitol and/or sorbitol. The use of “consisting of” limits the formulation to the listed components and any ingredients that do not materially alter the basic character of the formulation. Claims 8 and 21 cover a sealed vessel containing the formulation under a chemically inert dry gas. Claims 9 and 22 narrow the gas to nitrogen or argon. Claim architecture
What technical subject matter does the patent protect?The patent protects a quality and stability profile rather than a new cangrelor molecule. The technical focus is the control of degradation in a moisture-sensitive formulation. Moisture controlThe formulation claims require less than about 2.0% moisture by weight. The container claims use a less stringent post-storage limit, generally less than 5.0% moisture after six or 12 months. This creates two distinct infringement questions:
A formulation outside the initial moisture limit may avoid claims 1-7 and 14-20 even if it later satisfies the six- or 12-month storage limitations. pH controlThe claimed pH range is approximately 7.0 to 9.5. Claims 11-13 and 24-26 specify pH for a 1% solution by weight after 12 months. The pH limitation is potentially significant because it is tied to a test condition. A competing product cannot be evaluated solely on the pH of the dry powder. The relevant evidence would include the preparation of the 1% solution, the measurement method, the timing of measurement, and whether the claimed pH range is met after storage. Impurity controlThe claims identify five selected degradants:
Claim 1 uses a combined maximum of approximately 1.5%. Claim 2 narrows that threshold to approximately 1.3%. Claim 3 sets separate limits:
Claims 11-13 use different post-storage thresholds. Claim 11 limits impurities A through D to no more than 1% each and impurity E to no more than 0.5%. Claims 12 and 13 use aggregate limits of 5% and 2%, respectively. The claim language creates an analytical burden. A party evaluating infringement would need a validated assay capable of identifying and quantifying each named impurity, not merely total unspecified degradation products. How broad are the independent claims?Claim 1 is broad in formulation composition but narrow in quality attributes. It uses “comprising,” which generally permits additional excipients, buffers, stabilizers, or processing aids unless another limitation excludes them. The claim does not require:
The claim does require the combined technical profile of moisture, pH, cangrelor purity, and selected degradants. Claim 14 is narrower because it uses “consisting of” and identifies mannitol and/or sorbitol as the excipient system. It is more difficult to practice without falling within the claim if a competing product uses the same restricted composition, but it is easier to design around by using a different excipient system, subject to the broader claims 1-13. What formulations are protected by the patent?The most commercially relevant formulation is a cangrelor powder containing mannitol and/or sorbitol, with approximately 16-21% cangrelor and 84-79% excipient by weight. Key formulation coverage
A competing formulation using a different excipient may still infringe claim 1 if it satisfies the broad “one or more pharmaceutically acceptable excipients” language. Conversely, use of a different excipient may avoid claim 14, but it would not automatically avoid the broader claim family. When does US Patent 9,439,921 expire?The patent term must be calculated from the relevant nonprovisional filing date, adjusted for any patent-term adjustment and subject to any terminal disclaimer. Public patent records identify the patent as a post-1995 US patent governed by the 20-year term framework under 35 U.S.C. § 154.[3] The grant date, August 16, 2016, is not the expiration date. The practical expiration date is determined from the earliest effective nonprovisional priority date, not from the grant date. The patent record and USPTO Patent Center control the final expiration calculation, including any patent-term adjustment.[2] For commercial diligence, the relevant conclusion is that US 9,439,921 is a formulation patent with a term extending well beyond Kengreal’s three-year new-drug exclusivity period. FDA approval exclusivity for Kengreal began in 2015 and expired in 2018, while the patent term operates independently.[1][4] What is the Orange Book status of US 9,439,921?Kengreal is listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, under NDA 204958.[5] Orange Book listing is important because it can support a statutory patent certification process for an abbreviated new drug application. A generic applicant may be required to certify against listed patents under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The commercial impact depends on whether US 9,439,921 is listed for the relevant Kengreal presentation and whether the FDA accepts a generic applicant’s certification. A patent listed in the Orange Book does not establish validity or infringement. It gives the NDA holder a regulatory mechanism to receive notice of a Paragraph IV certification and potentially initiate litigation. What Paragraph IV challenges could target this patent?A generic applicant seeking approval before expiration could submit a Paragraph IV certification asserting that the patent is invalid, unenforceable, or not infringed.[4] The most likely challenge theories would focus on claim construction, obviousness, written description, enablement, indefiniteness, and noninfringement. Potential noninfringement strategiesA competing applicant could attempt to avoid the claims by:
Because claim 1 is a “comprising” claim, adding another excipient alone may not avoid infringement. A design-around based on excipients would be stronger against claim 14 than against claim 1. Potential validity argumentsA Paragraph IV challenger could examine:
The strongest validity issue would likely be whether the claimed combination of excipient composition, moisture, pH and impurity limits would have been obvious from prior cangrelor formulation work. The patent holder’s response would likely rely on the interaction among those parameters and the claimed storage stability. Does the patent cover cangrelor biosimilars?No. Cangrelor is a chemically synthesized small-molecule drug, not a biologic. A competing cangrelor product would generally proceed through the generic drug pathway under section 505(j), not the biosimilar pathway under section 351(k).[4][6] The relevant risks are therefore:
The Purple Book and biosimilar exclusivity concepts are not the primary regulatory framework for cangrelor. Which companies own or commercialize cangrelor?The Medicines Company developed and commercialized Kengreal after obtaining rights to the cangrelor program. Chiesi has commercial rights for Kengreal in relevant markets under arrangements involving The Medicines Company.[7]
Patent ownership and product commercialization are separate issues. A company commercializing Kengreal may not own every patent in the broader cangrelor landscape, and a patent assignment does not itself establish Orange Book listing or infringement. What patent litigation affects US 9,439,921?The key litigation risk is a future or existing Hatch-Waxman action following a Paragraph IV certification. A filing would typically trigger the statutory 45-day period for the NDA holder to bring an infringement action. A timely action can impose a 30-month stay on FDA approval, subject to statutory exceptions and court developments.[4] The supplied claim set alone does not establish that a Paragraph IV certification has been filed or that a final validity or infringement decision exists. Patent litigation status must be distinguished from patent status:
No settlement terms should be inferred solely from the existence of the patent or from Kengreal’s FDA listing. How strong is the patent estate for Kengreal?US 9,439,921 appears strategically important because it targets the commercial dosage-form attributes that a generic applicant must reproduce or sufficiently match for approval. Its strength is concentrated in formulation execution rather than molecule ownership. Strengths
Weaknesses
The estate is best characterized as a targeted formulation barrier. It is not a complete composition-of-matter barrier to cangrelor entry. How does US 9,439,921 compare with method-of-use and manufacturing patents?
US 9,439,921 does not claim the PCI indication, platelet inhibition generally, or the cangrelor molecule as such. Its commercial value depends on whether a competing applicant must use a formulation with the claimed stability profile. What generic launch scenarios exist?Scenario 1: Full formulation matchA generic applicant copies the core cangrelor-mannitol/sorbitol formulation and meets the claimed moisture, pH and impurity parameters. This creates the highest infringement risk and likely invites a Paragraph IV dispute if the patent remains listed and unexpired. Scenario 2: Excipient design-aroundThe applicant uses a different excipient system. This may avoid claim 14 and its dependents, but claim 1 remains relevant because it covers formulations with one or more pharmaceutically acceptable excipients. Scenario 3: Stability-profile design-aroundThe applicant uses a different process or formulation that produces a pH or impurity profile outside the claimed ranges. This may avoid literal infringement, but it must still satisfy FDA quality and stability requirements. Scenario 4: Post-expiration launchThe applicant waits until patent expiration or obtains a license. This removes the patent-based launch barrier but does not eliminate regulatory, manufacturing, supply-chain or commercial risks. What geographic coverage does the patent provide?US 9,439,921 provides protection only in the United States. Related foreign applications or national-stage patents may exist, but they must be assessed separately by jurisdiction. The relevant commercial jurisdictions for cangrelor may include:
A US patent does not prevent manufacture, sale or use outside the United States. It can, however, affect US importation, commercial launch, packaging, and supply from foreign manufacturing sites when the resulting product enters the US market. Key Takeaways
FAQsDoes US 9,439,921 claim Kengreal by brand name?No. The patent claims cangrelor formulations and sealed vessels meeting specified technical limitations. It does not depend on the Kengreal trademark. Can a generic use cangrelor with an excipient other than mannitol or sorbitol?Potentially. A different excipient may avoid the narrower claims directed to mannitol and/or sorbitol, but the broader formulation claims must still be analyzed. Is a cangrelor injectable product automatically covered by this patent?No. The product must satisfy each limitation of at least one asserted claim, including the moisture, pH and impurity requirements where applicable. Are impurities A through E ordinary cangrelor impurities?They are selected hydrolysis and oxidation degradants identified by the patent. Their exact chemical identities and analytical methods must be determined from the patent specification and associated regulatory documentation. Does patent expiration eliminate all barriers to generic cangrelor entry?No. Expiration removes the patent barrier for the expired claims, but FDA approval requirements, manufacturing capacity, API supply, quality validation and commercial contracting remain relevant. References
More… ↓ |
Drugs Protected by US Patent 9,439,921
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chiesi | KENGREAL | cangrelor | POWDER;INTRAVENOUS | 204958-001 | Jun 22, 2015 | AP | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,439,921
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Brazil | 112017014996 | ⤷ Start Trial | |||
| Canada | 2971868 | ⤷ Start Trial | |||
| Chile | 2017001840 | ⤷ Start Trial | |||
| China | 107206014 | ⤷ Start Trial | |||
| China | 115990138 | ⤷ Start Trial | |||
| Colombia | 2017006958 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
